December 11th, 2024

Having a good breakfast reduces cardiovascular risk

Consuming 20-30% of daily energy intake in the morning influences key cardiovascular risk factors. People who consume the right amount of energy in the morning have 2-3.5% lower body mass index, less abdominal obesity (2-4% smaller waist circumference), 9-18% lower triglycerides, and 4-8.5% higher HDL cholesterol (the good cholesterol). Additionally, having a high-quality breakfast with a balanced intake of proteins, high-value fats, fiber, calcium, and iron is associated with a 1.5% smaller waist circumference, 4% lower triglycerides, and 3% higher HDL cholesterol. The study tracked nearly 400 participants of the PREDIMED-Plus study over three years, which analyzes the effects of the Mediterranean diet on participants' health.

Read more sobre "Having a good breakfast reduces cardiovascular risk"

November 18th, 2024

Novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors

The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by VHIO investigators, CAR T cells targeting p95HER2 have been engineered to secrete the TECH2Me bispecific antibody. Both therapies specifically and independently recognize tumor cells. In addition, the TECH2Me bispecific antibody activates immune cells within the tumor microenvironment.  This dual mechanism of action has demonstrated safety and achieved complete and durable antitumor responses in patient-derived models of HER2+ p95HER2-expressing solid tumors. Published in Nature Communications, results of this VHIO-led study have provided the rationale for the application of a phase 1 first-in-human clinical trial, currently in the approval process, to assess this novel therapeutic strategy in patients with HER2-driven solid tumors. This study is mainly supported by the Asociación Española Contra el Cáncer (AECC) through AUSONIA and has also received funding from the Breast Cancer Research Foundation (BCRF), Fundación BBVA through the Comprehensive Program of Cancer Immunotherapy and Immunology (CAIMI), which is one of VHIO's Institutional Programs focused on developing new advanced therapies.

Read more sobre "Novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors"

November 6th, 2024

Hospital del Mar to Coordinate a €10 Million Study to Develop Blood Stem Cells in the Laboratory

This study will be conducted in collaboration with the Josep Carreras Leukemia Research Institute, and researchers from Finland, the Netherlands, and the United Kingdom will participate. The goal is to develop and validate protocols and systems for generating laboratory-derived stem cells to regenerate patients' blood. The European Research Council, which provides these grants, is the leading funding organization for advanced and excellent research on the continent. It is an organization created by the European Union.

Read more sobre "Hospital del Mar to Coordinate a €10 Million Study to Develop Blood Stem Cells in the Laboratory"

Acto de reconocimiento: Excelencia en la implementación del decálogo para la eliminación de la hepatitis C

17 de diciembre de 2024

Curso en Disfagia Orofaríngea del Hospital del Mar

13 de diciembre de 2024

Mitos y realidades en la alimentación durante el cáncer

19 de diciembre del 2024